Navigation Links
China's Rheumatoid Arthritis Drug Market Will More than Double by 2013
Date:7/13/2009

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) drug market will more than double by 2013, growing from $138 million in 2008 to $385 million in 2013. This growth will be fueled by a growing drug-treated population, increasing patient access to healthcare insurance, greater patient spending power and increased use of biological agents in RA treatment.

"A principal driver of growth in the Chinese RA market is the expanding patient population. We expect the number of patients eligible for drug therapy to increase 52 percent by 2013. During the same 2008-2013 time period, the drug-treated population will grow approximately 80 percent," stated Jing Wu, M.S., MBA.

The new Emerging Markets report entitled Rheumatoid Arthritis in China also finds that Western branded drug sales will command 54 percent of the market by 2013. The key drivers of this growth will be the increased uptake of currently available Western branded biologics and the launch of new biologics. The best opportunities for Western drug companies are in the launch and marketing of new biological agents that are easily administered and have novel mechanisms of action that achieve quicker onset of disease-modifying activity.

"We expect less competition from Chinese generic versions of new Western branded biologics than for small-molecule drugs for two reasons: biologics are harder to imitate than small chemical molecules and it is difficult to convince physicians that biosimilars have the same activity as the original brands," added Ms. Wu.

The report contains primary research of physicians and epidemiology study in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                 Elizabeth Marshall
    Decision Resources               Decision Resources, Inc.
    781-296-2691                     781-296-2563
    gmorales@dresources.com          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New Drug Promising Against Rheumatoid Arthritis
3. Over half of people with rheumatoid arthritis have periodontitis
4. Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis
5. Rheumatoid arthritis is associated with poor sleep in women
6. Rheumatoid Arthritis Drug Might Fight Swine Flu
7. Treating gum disease helps rheumatoid arthritis sufferers
8. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
9. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
10. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
11. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to ... youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and ... involved in violence in the United States. The study, Trends in Fighting ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Dudnyk has announced ... emphasizes the agency’s conviction that the full potential of specialty and orphan brands can ... appreciated and aligned. , “The Unifying Effect is at the heart of a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology: